treating Parkinson's disease AFTER the "honeymoon" is over

September 2011

You'll see more emphasis on treating Parkinson's disease AFTER the "honeymoon" is over.

For the first few years, symptoms are usually well controlled with low doses of carbidopa/levodopa or a dopamine agonist (pramipexole, etc).

But eventually drug efficacy decreases as the disease progresses.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Cardiology the risk of stopping aspirin, clopidogrel, or other antiplatelet drugs too soon
Hepatitis C two new protease inhibitors for chronic hepatitis C, Incivek (telaprevir) and Victrelis (boceprevir)
Statins the interaction between simvastatin (Zocor, etc) and amlodipine (Norvasc, Twynsta, etc)
Migraine Axert (almotriptan) is now the first triptan approved for treating migraines in adolescents
Gastroenterology stronger warnings from Health Canada about movement disorders with metoclopramide
Acetaminophen new lower dosing on Tylenol (acetaminophen) products
Infectious Diseases the emergence of a new strain of ceftriaxone-resistant gonorrhea
Geriatrics "START" and "STOPP" instead of the Beers criteria to evaluate appropriate med use in the elderly
Psychiatry stronger warnings about quetiapine (Seroquel, etc) and QT prolongation
Anticoagulants how to reverse bleeding due to Pradax or Xarelto
Parkinson's Disease treating Parkinson's disease AFTER the "honeymoon" is over
Oral Health new topical cold sore ointment called ColdSore-FX